FRACTALKINE: PATHOGENIC ROLE AND DIAGNOSTIC CAPABILITIES
https://doi.org/10.25207/1608-6228-2017-2-148-151
Abstract
The review presents modern data on the pathogenic role of CC chemokine is CX3CL1 or fractalkine in the cascade of immune responses in various diseases. The material presented sistematizirovat the most significant results of the work of clinical diagnostic value fractalkine in pathological conditions. At the same time, in the literature very little information on clinical research studies of the content of chemokines in the serum in allergic skin diseases, the available data are inconsistent, and information about research of this kind in pediatric patients are not available. The authors draw attention to the possibility of using fractalkine as a marker of inflammatory activity and a prognostic factor for atopic dermatitis.
About the Authors
O. A. MESNYANKINA
"Astrakhan state medical University" Ministry of health of Russia
Russian Federation
Russian Federation
The Department of dermatology and venereology
414000, Astrakhan, street Bakinskaya, 121; tel: +7 (8512) 52-41-43
E. Yu. YANCHEVSKAYA
"Astrakhan state medical University" Ministry of health of Russia
Russian Federation
Russian Federation
The Department of dermatology and venereology
414000, Astrakhan, street Bakinskaya, 121; tel: +7 (8512) 52-41-43
M. BEN
"Astrakhan state medical University" Ministry of health of Russia
Russian Federation
Russian Federation
The Department of dermatology and venereology
414000, Astrakhan, street Bakinskaya, 121; tel: +7 (8512) 52-41-43
References
1. Дегтярев О. В., Меснянкина О. А. Диспротеинемия как один из факторов патогенеза псориаза // Российский журнал кожных и венерических болезней. – 2014. – Т.17, № 5. – С. 36–39.
2. Журавлева Л. В., Лопина Н. А.Уровень фракталкина и его значение в прогнозировании наличия и выраженности атеросклеротического поражения венечных сосудов // Украинский кардиологичесикй журнал. – 2016. – № 4. – С. 62–67.
3. Ковальчук Л. В. Хемокины – новое семейство цитокинов, регулирующих миграцию лейкоцитов // Микробиология. – 2000. – № 1. – С. 90–94.
4. Кухтина Н. Б., Арефьева Т. И., Рулева Н. Ю., Сидорова М. В., Азьмуко А. А., Беспалова Ж. Д., Красникова Т. Л. Пептидные фрагменты хемокинового домена фракталкина: влияние на миграцию моноцитов человека // Биоорг. Химия. – 2012. – Т.38, № 6. – С. 660–666.
5. Севостьянова И. В., Полунина О. С., Воронина Л. П., Перова Н. Ю., Белякова И. С., Полунина Е. А. Влияние цитокинов к хемотаксическими свойствами на состояние сосудистого эндотелия при бронхиальной астме //Астраханский мед. журнал. – 2014. – Т.9, № 3. – С. 56–62.
6. Суколина О.Г. Состояние оксида азота и адаптивных беков при псориазе // Вестн. дерматол. венерол. – 2005. – № 5. – С. 15–18.
7. Bazan J.F., Bacon K.B., Hardiman G. A new class of membrane-bound chemokine with a CX3C motif // Nature. – 1997. – Vol. 385, № 6617. – Р. 640–644.
8. Bjerkeli V., Dam Мs J. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis– possible role in vascular inflammation // Rheumatology (Oxford). – 2007. – Vol. 46, N9. – P. 1422–1427.
9. Chong S., Lan H., Zeng K., Zhao X. Serum Fractalkine (CX3CL1) Concentration Correlates with Clinical Severity in Pediatric Atopic Dermatitis Patients // Ann. Clin. Lab. Sci. – 2016. – Vol.46, № 2. – Р. 168–73.
10. Echigo T., Hasegawa M., Shimada Y., Takehara K., Sato S. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation // J. Allergy Clin. Immunol. –2004. – Vol. 113, N 5. – P. 940–948.
11. El-Shazly A., Berger P. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma // J. Immunol. – 2006. – Vol. 176, № 3. – P. 1860–1868.
12. Green S. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK // J. Immunol. – 2006. – Vol. 176, № 12. – P. 7412–7420.
13. Hatori K, Nagai A, Heisel R et al. Fractalkine and fractalkine receptors in human neurons and glial cells // J. Neurosci Res. – 2002. – Vol. 69, N3. – P. 418–26.
14. Huang Y., Cai X., Chen P. et al. Associations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis // Ann. Medicine. – 2014. – Vol. 46. – P. 684–692.
15. Hyakudomi M, Matsubara T, Hyakudomi R et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma //Ann. Surg. Oncol. – 2008. – Vol. 15, № 6. – P. 1775–1782.
16. Ikejima H., Imanishi T., Tsujioka H. et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris // Circulation J. – 2010. – Vol. 74. – Р. 337–345.
17. Imai T, Hieshima K, Haskel C et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion // Cell. – 1997. – Vol. 91, № 4. – P. 521–530.
18. Janeway C., Travers P., Walport M., Shlomchik M.J. Immunobiology: the immune system in health and disease. 6th ed., 2005. – P. 77–79.
19. Julia V., Staumont-Salle D., Dombrowicz D. Role of fractalkine/CX3CL1 and its receptor CX3CR1 in allergic diseases // Med Sci (Paris). – 2016. – Vol. 32, № 3. – P. 260–266.
20. Kim J., Kim J., Cho D., Park H. Molecular mechanisms of cutaneous inflammatory disorder atopic dermatitis // Int. J. of Molecular Sciences. – 2016. – Vol.17, №8. – P. 1234.
21. Locati M., Murphy P.M. Chemokines and chemokine receptors: Biology and clinical relevance in inflammation and AIDS // Annu Rev. Med. – 1999. – Vol. 50. – P. 425–440.
22. Matsubara T., Ono T. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma // J. Surg. Oncol. – 2007. – Vol. 95, №3. – P. 241–249.
23. Mizutani N., Sakurai T., Shibata T. et al. Dose-dependent differential regulation of cytokine secretion from macrophages by Fractalkine // Immunol. – 2007. – Vol. 179, № 11. – P. 7478–7487.
24. Pachot A., Cazalis M.A., Venet F. et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression // J. Immunol. – 2008. – Vol. 180, № 9. – P. 6421–6429.
25. Perros F., Dorfmuller P., Souza R. et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension // Eur. Respir. J. – 2007. – Vol. 29, № 5. – P. 937–943.
26. Plant D., Pfleger С., Hougaard P., Hansen L. The CX3CL1-CX3CR1 system and psoriasis // Exp Dermatol. – 2006. – Vol. 15, № 11. – Р. 900–903.
27. Ruster C., Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy // Front Biosci. – 2008. – Vol.13. – P.944-955.
28. Raychaudhuri S.P., Jiang W.Y., Farber E.M. Cellularlocalization of fractalkine at sites of inflammation:antigenpresenting cells in psoriasis express high levelsof fractalkine // Br. J. Dermatol. – 2001. – Vol. 144. – P. 1105–1113.
29. Sans M., Danese S. Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease // Gastroenterology. – 2007. – Vol. 132, № 1. – P. 139–153.
30. Savarin-Vuaillat C., Ransohoff R.M. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? // Neurotherapeutics. – 2007. – Vol 4, №4. – P. 590–601.
31. Sawai H., Park Y.W., He X. et al. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis //Arthritis Rheum. – 2007. – Vol. 56, № 10. – P. 3215–3225.
32. Schall T. Fractalkine–a strange attractor in the chemokine landscape //Immunol. Today. – 1997. – Vol.18, № 4. – P. 147.
33. Staumont-Sallé D., Fleury S., Lazzari A. et al. CX3CR1 (fractalkine) and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin // J. Exp. Med. – 2014. – Vol. 211, № 6.– P. 1185–96.
34. Sugaya M. Chemokines and skin diseases // Arch. Immunol. Ther. Exp. (Warsz). – 2015. – Vol.63, № 2. – P. 109–115.
35. Yoshimoto S., Nakatani K., Iwano M. et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis // Am. J. Kidney Dis. – 2007. – Vol.50, № 1. – P.47–58.
Review
For citations:
MESNYANKINA O.A., YANCHEVSKAYA E.Yu., BEN M. FRACTALKINE: PATHOGENIC ROLE AND DIAGNOSTIC CAPABILITIES. Kuban Scientific Medical Bulletin. 2017;1(2):148-151. (In Russ.) https://doi.org/10.25207/1608-6228-2017-2-148-151
Views:
1058
Email this article 